239 related articles for article (PubMed ID: 36835131)
1. HER2 Expression in Bladder Cancer: A Focused View on Its Diagnostic, Prognostic, and Predictive Role.
Sanguedolce F; Zanelli M; Palicelli A; Bisagni A; Zizzo M; Ascani S; Pedicillo MC; Cormio A; Falagario UG; Carrieri G; Cormio L
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835131
[TBL] [Abstract][Full Text] [Related]
2. Human Epidermal Growth Factor Receptor 2 in Non-Muscle Invasive Bladder Cancer: Issues in Assessment Methods and Its Role as Prognostic/Predictive Marker and Putative Therapeutic Target: A Comprehensive Review.
Sanguedolce F; Russo D; Mancini V; Selvaggio O; Calò B; Carrieri G; Cormio L
Urol Int; 2019; 102(3):249-261. PubMed ID: 30463072
[TBL] [Abstract][Full Text] [Related]
3. Expression of epidermal growth factor receptor and human epidermal growth factor receptor 2 in urothelial bladder carcinoma in an Egyptian cohort: Clinical implication and prognostic significance.
Sami MM; Sherief MH; El-Abaseri TB; El-Sakka AI; El-Serafi AT
Urologia; 2023 May; 90(2):248-260. PubMed ID: 36670543
[TBL] [Abstract][Full Text] [Related]
4. Value of multicolour fluorescence in situ hybridisation (UroVysion) in the differential diagnosis of flat urothelial lesions.
Schwarz S; Rechenmacher M; Filbeck T; Knuechel R; Blaszyk H; Hartmann A; Brockhoff G
J Clin Pathol; 2008 Mar; 61(3):272-7. PubMed ID: 17693577
[TBL] [Abstract][Full Text] [Related]
5. HER2 Affects the Biological Behaviours of Bladder Cancer Cells and is Closely Associated with the Progression and Prognosis of Bladder Cancer.
Li Q; Su X; Qing L; Xu W; Yang Y; You C; Wang J; Dong Z
Arch Esp Urol; 2024 Jan; 77(1):79-91. PubMed ID: 38374017
[TBL] [Abstract][Full Text] [Related]
6. HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic implications.
Krüger S; Weitsch G; Büttner H; Matthiensen A; Böhmer T; Marquardt T; Sayk F; Feller AC; Böhle A
Int J Cancer; 2002 Dec; 102(5):514-8. PubMed ID: 12432555
[TBL] [Abstract][Full Text] [Related]
7. [Expression of Her2/neu in locally advanced bladder cancer: implication for a molecular targeted therapy].
Wülfing C; von Struensee D; Bierer S; Bögemann M; Hertle L; Eltze E
Aktuelle Urol; 2005 Sep; 36(5):423-9. PubMed ID: 16163605
[TBL] [Abstract][Full Text] [Related]
8. Human Epidermal Growth Factor Receptor 2 Overexpression in Micropapillary and Other Variants of Urothelial Carcinoma.
Behzatoğlu K; Yörükoğlu K; Demir H; Bal N
Eur Urol Focus; 2018 Apr; 4(3):399-404. PubMed ID: 28753766
[TBL] [Abstract][Full Text] [Related]
9. Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma?
Gandour-Edwards R; Lara PN; Folkins AK; LaSalle JM; Beckett L; Li Y; Meyers FJ; DeVere-White R
Cancer; 2002 Sep; 95(5):1009-15. PubMed ID: 12209684
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical based molecular subtypes of muscle-invasive bladder cancer: association with HER2 and EGFR alterations, neoadjuvant chemotherapy response and survival.
Helal DS; Darwish SA; Awad RA; Ali DA; El-Guindy DM
Diagn Pathol; 2023 Feb; 18(1):11. PubMed ID: 36737799
[TBL] [Abstract][Full Text] [Related]
11. Clinical Significance of Substaging and HER2 Expression in Papillary Nonmuscle Invasive Urothelial Cancers of the Urinary Bladder.
Lim SD; Cho YM; Choi GS; Park HK; Paick SH; Kim WY; Kim SN; Yoon G
J Korean Med Sci; 2015 Aug; 30(8):1068-77. PubMed ID: 26240484
[TBL] [Abstract][Full Text] [Related]
12. Bladder Tumor Subtype Commitment Occurs in Carcinoma
Wullweber A; Strick R; Lange F; Sikic D; Taubert H; Wach S; Wullich B; Bertz S; Weyerer V; Stoehr R; Breyer J; Burger M; Hartmann A; Strissel PL; Eckstein M
Cancer Res; 2021 Mar; 81(6):1552-1566. PubMed ID: 33472889
[TBL] [Abstract][Full Text] [Related]
13. Effect of HER2 and Fascin expression on muscle-invasive bladder cancers: Classification by basaloid and luminal phenotypes.
Arslan AI; Karabağ S; Akgül M
Indian J Pathol Microbiol; 2022; 65(3):604-609. PubMed ID: 35900488
[TBL] [Abstract][Full Text] [Related]
14. Predicting progression of bladder urothelial carcinoma using microRNA expression.
Rosenberg E; Baniel J; Spector Y; Faerman A; Meiri E; Aharonov R; Margel D; Goren Y; Nativ O
BJU Int; 2013 Nov; 112(7):1027-34. PubMed ID: 23387295
[TBL] [Abstract][Full Text] [Related]
15. Morphological and molecular characteristics of HER2 amplified urothelial bladder cancer.
Tschui J; Vassella E; Bandi N; Baumgartner U; Genitsch V; Rotzer D; Seiler R; Thalmann GN; Fleischmann A
Virchows Arch; 2015 Jun; 466(6):703-10. PubMed ID: 25809292
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Role of Survivin and Macrophage Infiltration Quantified on Protein and mRNA Level in Molecular Subtypes Determined by RT-qPCR of
Ecke TH; Kiani A; Schlomm T; Friedersdorff F; Rabien A; Jung K; Kilic E; Boström P; Tervahartiala M; Taimen P; Gleichenhagen J; Johnen G; Brüning T; Koch S; Roggisch J; Wirtz RM
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33050010
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathologic and Immunohistochemical Study of Combined Small Cell Carcinoma and Urothelial Carcinoma Molecular Subtype.
Xiao GQ; Barrett MM; Yang Q; Unger PD
Pathol Oncol Res; 2019 Jul; 25(3):889-895. PubMed ID: 29249035
[TBL] [Abstract][Full Text] [Related]
18. Triple-marker immunohistochemical assessment of muscle-invasive bladder cancer: Is there prognostic significance?
Labban M; Najdi J; Mukherji D; Abou-Kheir W; Tabbarah A; El-Hajj A
Cancer Rep (Hoboken); 2021 Apr; 4(2):e1313. PubMed ID: 33538412
[TBL] [Abstract][Full Text] [Related]
19. Fatty acid synthase, Her2/neu, and E2F1 as prognostic markers of progression in non-muscle invasive bladder cancer.
Abdelrahman AE; Rashed HE; Elkady E; Elsebai EA; El-Azony A; Matar I
Ann Diagn Pathol; 2019 Apr; 39():42-52. PubMed ID: 30684846
[TBL] [Abstract][Full Text] [Related]
20. Her2 amplification distinguishes a subset of non-muscle-invasive bladder cancers with a high risk of progression.
Chen PC; Yu HJ; Chang YH; Pan CC
J Clin Pathol; 2013 Feb; 66(2):113-9. PubMed ID: 23087329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
